Firebrick Pharma (ASX:FRE)
ASX announcement history & article coverage
Transparent by design.
Announcments by Firebrick Pharma (ASX:FRE) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4G
Corporate Governance Statement
Appendix 4E and Annual Report 30 June 2026
Firebrick Pharma reports $3.06 million loss with early Nasodine commercialisation progress and $3.17 million capital raised
Cleansing Notice
Application for quotation of securities - FRE
Proposed issue of securities - FRE
Update - Notification regarding unquoted securities - FRE
Investor Update
Firebrick Pharma advances Nasodine commercialisation with US sales growth and Southeast Asia expansion
June 2026 Quarterly Activity Report
Firebrick Pharma reports patent grants, 43% sales growth, and stable cash burn in June 2026 quarter
Change of Address
Results of General Meeting
Nasodine Composition Patent Granted in New Zealand
Cleansing Notice
Application for quotation of securities - FRE
Proposed issue of securities - FRE
Notification of cessation of securities - FRE